InsiderTrades.com logo
David Shook net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

David Shook Biography and Net Worth

Insider of Lyell Immunopharma

David Shook, M.D., has served as our Chief Medical Officer since June 2025. He is an early pioneer of cell therapy and remains a practicing pediatric oncologist and transplant physician. Prior to Lyell, Dr. Shook held several senior roles at Nkarta between 2020 and 2025, most recently as Chief Medical Officer and Head of Research and Development, where he was responsible for leading the clinical development of multiple CAR NK cell product candidates for oncology. Prior to Nkarta, Dr. Shook held roles as Medical Director, Pediatric Cellular Therapy at AdventHealth between 2015 and 2020, and from 2007 to 2015 he held faculty positions at St. Jude Children’s Research Hospital including Fellowship Director, Pediatric Bone Marrow Transplantation and Cellular Therapy, and Assistant Member, Department of Bone Marrow Transplantation & Cellular Therapy. While at St. Jude, he conducted multiple first-in-human cell therapy trials as well as research in the laboratory of Dario Campana, M.D., Ph.D. where he co-developed the membrane bound form of interleukin-15. He earned an M.D. from The Johns Hopkins University School of Medicine and a B.S. from Purdue University.

What is David Shook's net worth?

The estimated net worth of David Shook is at least $266.14 thousand as of June 10th, 2026. Dr. Shook owns 20,923 shares of Lyell Immunopharma stock worth more than $266,141 as of June 17th. This net worth evaluation does not reflect any other assets that Dr. Shook may own. Learn More about David Shook's net worth.

How do I contact David Shook?

The corporate mailing address for Dr. Shook and other Lyell Immunopharma executives is , , . Lyell Immunopharma can also be reached via phone at 650-695-0677 and via email at [email protected]. Learn More on David Shook's contact information.

Has David Shook been buying or selling shares of Lyell Immunopharma?

In the last ninety days, David Shook has sold $24,989.28 in Lyell Immunopharma stock. Most recently, David Shook sold 1,977 shares of the business's stock in a transaction on Wednesday, June 10th. The shares were sold at an average price of $12.64, for a transaction totalling $24,989.28. Following the completion of the sale, the insider now directly owns 20,923 shares of the company's stock, valued at $264,466.72. Learn More on David Shook's trading history.

Who are Lyell Immunopharma's active insiders?

Lyell Immunopharma's insider roster includes Otis Brawley (Director), Otis Brawley (Director), Stephen Hill (COO), Richard Klausner (Director), Richard Klausner (Founder & Board Chair), Gary Lee (Insider), Charles Newton (CFO), Charles Newton (CFO), Sumant Ramachandra (Director), Lynn Seely (President & Chief Executive Officer), Lynn Seely (CEO), and David Shook (Insider). Learn More on Lyell Immunopharma's active insiders.

Are insiders buying or selling shares of Lyell Immunopharma?

In the last twelve months, insiders at the sold shares 24 times. They sold a total of 16,511 shares worth more than $334,921.75. The most recent insider tranaction occured on June, 10th when insider David Shook sold 1,977 shares worth more than $24,989.28. Insiders at Lyell Immunopharma own 6.2% of the company. Learn More about insider trades at Lyell Immunopharma.

Information on this page was last updated on 6/10/2026.

David Shook Insider Trading History at Lyell Immunopharma

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/10/2026Sell1,977$12.64$24,989.2820,923View SEC Filing Icon  
See Full Table

David Shook Buying and Selling Activity at Lyell Immunopharma

This chart shows David Shook's buying and selling at Lyell Immunopharma by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Lyell Immunopharma Company Overview

Lyell Immunopharma logo
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications. In addition, the company's preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $12.50
Low: $12.31
High: $13.02

50 Day Range

MA: $18.85
Low: $11.97
High: $24.89

2 Week Range

Now: $12.50
Low: $8.46
High: $45.00

Volume

87,259 shs

Average Volume

98,551 shs

Market Capitalization

$291.53 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A